Structure Therapeutics Inc. financial data

Symbol
GPCR on Nasdaq
Industry
Pharmaceutical Preparations
Location
611 Gateway Blvd Suite 223, South San Francisco, CA
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
ShouTi Inc. (to 5/13/2022)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.27K %
Debt-to-equity 5.3 %
Return On Equity -20.1 % +82.2%
Return On Assets -19.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172M shares +49.5%
Common Stock, Shares, Outstanding 172M shares
Entity Public Float 502M USD
Common Stock, Value, Issued 17K USD
Weighted Average Number of Shares Outstanding, Basic 148M shares +29.2%
Weighted Average Number of Shares Outstanding, Diluted 148M shares +29.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 80.3M USD +60.4%
General and Administrative Expense 42.2M USD +98.8%
Operating Income (Loss) -122M USD -71.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -100M USD -53%
Income Tax Expense (Benefit) 175K USD +386%
Net Income (Loss) Attributable to Parent -100M USD -53.2%
Earnings Per Share, Basic -0.73 USD/shares +74.7%
Earnings Per Share, Diluted -0.73 USD/shares +74.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 382M USD +840%
Cash, Cash Equivalents, and Short-term Investments 927M USD +313%
Assets, Current 938M USD +311%
Property, Plant and Equipment, Net 3.32M USD +208%
Operating Lease, Right-of-Use Asset 4.27M USD +4641%
Other Assets, Noncurrent 1.83M USD +4705%
Assets 947M USD +313%
Accounts Payable, Current 2.21M USD -61.2%
Employee-related Liabilities, Current 4.01M USD +78.3%
Liabilities, Current 22.7M USD +50.9%
Operating Lease, Liability, Noncurrent 3.05M USD
Other Liabilities, Noncurrent 293K USD
Liabilities 26M USD +73.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -487K USD -24.9%
Retained Earnings (Accumulated Deficit) -259M USD -63.5%
Stockholders' Equity Attributable to Parent 921M USD +330%
Liabilities and Equity 947M USD +313%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.1M USD -67.8%
Net Cash Provided by (Used in) Financing Activities 702K USD -99.6%
Net Cash Provided by (Used in) Investing Activities 1.42M USD
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 172M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32M USD -132%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 382M USD +840%
Deferred Tax Assets, Valuation Allowance 51.6M USD +85.8%
Deferred Tax Assets, Gross 52.8M USD +89.1%
Operating Lease, Liability 4.67M USD +6303%
Depreciation 222K USD +217%
Payments to Acquire Property, Plant, and Equipment 162K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -101M USD -52.7%
Lessee, Operating Lease, Liability, to be Paid 5.16M USD +6873%
Property, Plant and Equipment, Gross 4.41M USD +181%
Operating Lease, Liability, Current 1.63M USD +2132%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.89M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.93M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 486K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 381K USD
Deferred Tax Assets, Operating Loss Carryforwards 29.2M USD +54.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares +8%
Unrecognized Tax Benefits 877K USD +203%
Lessee, Operating Lease, Liability, to be Paid, Year Four 384K USD
Operating Lease, Payments 300K USD +200%
Additional Paid in Capital 1.18B USD +216%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.22M USD +637%
Share-based Payment Arrangement, Expense 10.9M USD +98.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%